MannKind (MNKD) Set to Announce Earnings on Wednesday

MannKind (NASDAQ:MNKD) will issue its quarterly earnings data before the market opens on Wednesday, August 7th. Analysts expect the company to announce earnings of $0.01 per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.

MannKind (NASDAQ:MNKD) last released its earnings results on Wednesday, May 8th. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.03 by $0.02. The firm had revenue of $66.26 million during the quarter, compared to the consensus estimate of $60.55 million. MannKind had a net margin of 3.78% and a negative return on equity of 3.35%. MannKind’s revenue was up 63.1% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.04) earnings per share. On average, analysts expect MannKind to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MannKind Trading Up 2.1 %

Shares of MNKD traded up $0.11 during mid-day trading on Tuesday, reaching $5.34. The company had a trading volume of 1,588,058 shares, compared to its average volume of 2,702,951. MannKind has a fifty-two week low of $3.17 and a fifty-two week high of $6.04. The firm has a fifty day simple moving average of $5.21 and a 200-day simple moving average of $4.54. The stock has a market cap of $1.45 billion, a price-to-earnings ratio of 178.73 and a beta of 1.32.

Insider Buying and Selling

In other news, EVP David Thomson sold 23,537 shares of MannKind stock in a transaction that occurred on Tuesday, May 21st. The shares were sold at an average price of $4.66, for a total transaction of $109,682.42. Following the sale, the executive vice president now owns 873,616 shares in the company, valued at $4,071,050.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last ninety days, insiders have sold 29,991 shares of company stock valued at $142,093. Corporate insiders own 3.00% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on MNKD. Rodman & Renshaw assumed coverage on MannKind in a research report on Thursday, June 13th. They set a “buy” rating and a $8.00 price target for the company. Cantor Fitzgerald reissued an “overweight” rating and set a $6.50 target price on shares of MannKind in a research report on Thursday, May 9th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, MannKind currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.00.

MannKind Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults.